المؤلفون: Rogowski W; Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland., Wachuła E; Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland., Lewczuk A; Department of Endocrinology, Medical University of Gdansk, Gdansk, Poland., Buscombe JR; Department of Nuclear Medicine & PET, Addenbrooke's Hospital, Cambridge, UK., Seklecka N; Department of Radiology & Diagnostic Imaging, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland., Sankowski A; Department of Radiology & Diagnostic Imaging, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland., Ćwikła JB; Faculty of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.

المصدر: Future oncology (London, England) [Future Oncol] 2016 Aug; Vol. 12 (16), pp. 1877-85. Date of Electronic Publication: 2016 May 09.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Intestinal Neoplasms/*drug therapy , Neuroendocrine Tumors/*drug therapy , Octreotide/*analogs & derivatives , Organometallic Compounds/*therapeutic use , Pancreatic Neoplasms/*drug therapy, Disease-Free Survival ; Female ; Humans ; Intestinal Neoplasms/mortality ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neuroendocrine Tumors/mortality ; Octreotide/therapeutic use ; Pancreatic Neoplasms/mortality ; Proportional Hazards Models ; Radiopharmaceuticals/therapeutic use